Oncogenic Y68 frame shift mutation of PTEN represents a mechanism of docetaxel resistance in endometrial cancer cell lines

[1]  H. Kuramoto,et al.  PI3K/mTOR pathway inhibition overcomes radioresistance via suppression of the HIF1-α/VEGF pathway in endometrial cancer. , 2015, Gynecologic oncology.

[2]  Zhenyu Zhang,et al.  Sequential Chemotherapy and Radiotherapy in the Sandwich Method for Advanced Endometrial Cancer-Analysis , 2015 .

[3]  Jia-Lin Yang,et al.  Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer , 2015, Journal of Cancer Research and Clinical Oncology.

[4]  M. Ark,et al.  xCELLigence Real Time Cell Analysis System: A New Method for Cell Proliferation and Cytotoxicity , 2014 .

[5]  A. Markowska,et al.  Signalling pathways in endometrial cancer , 2014, Contemporary oncology.

[6]  Young Tae Kim,et al.  The benefit of adjuvant chemotherapy combined with postoperative radiotherapy for endometrial cancer: a meta-analysis. , 2013, European journal of obstetrics, gynecology, and reproductive biology.

[7]  Julian Downward,et al.  PI3K Pathway Dependencies in Endometrioid Endometrial Cancer Cell Lines , 2013, Clinical Cancer Research.

[8]  Steven J. M. Jones,et al.  Integrated genomic characterization of endometrial carcinoma , 2013, Nature.

[9]  R. Finn,et al.  Activity of the Fibroblast Growth Factor Receptor Inhibitors Dovitinib (TKI258) and NVP-BGJ398 in Human Endometrial Cancer Cells , 2013, Molecular Cancer Therapeutics.

[10]  R. Coleman,et al.  The PI3K/AKT/mTOR Pathway as a Therapeutic Target in Endometrial Cancer , 2012, Clinical Cancer Research.

[11]  J. Trovik,et al.  Markers for individualised therapy in endometrial carcinoma. , 2012, The Lancet. Oncology.

[12]  W. Fan,et al.  G2 checkpoint abrogator abates the antagonistic interaction between antimicrotubule drugs and radiation therapy. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[13]  P. Pandolfi,et al.  The functions and regulation of the PTEN tumour suppressor , 2012, Nature Reviews Molecular Cell Biology.

[14]  T. Herzog,et al.  Contemporary management of endometrial cancer , 2012, The Lancet.

[15]  G. Mills,et al.  High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. , 2011, Cancer discovery.

[16]  A. Ashworth,et al.  Emerging therapeutic targets in endometrial cancer , 2011, Nature Reviews Clinical Oncology.

[17]  P. Zola,et al.  Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies. , 2010, European journal of cancer.

[18]  K. Dusenbery,et al.  A single institution experience using sequential multi-modality adjuvant chemotherapy and radiation in the "sandwich" method for high risk endometrial carcinoma. , 2010, Gynecologic oncology.

[19]  Kristian Cibulskis,et al.  Drug-sensitive FGFR2 mutations in endometrial carcinoma , 2008, Proceedings of the National Academy of Sciences.

[20]  G. Yang,et al.  Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells , 2008, British Journal of Cancer.

[21]  P. Pollock,et al.  Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes , 2007, Oncogene.

[22]  Xiao Xu,et al.  Dynamic and label-free cell-based assays using the real-time cell electronic sensing system. , 2006, Assay and drug development technologies.

[23]  M. E. King,et al.  Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study. , 2005, Gynecologic oncology.

[24]  A. Tarnawski,et al.  PTEN regulatory functions in tumor suppression and cell biology. , 2004, Medical science monitor : international medical journal of experimental and clinical research.

[25]  W. Fan,et al.  Cell Cycle–Dependent Antagonistic Interactions between Paclitaxel and γ-Radiation in Combination Therapy , 2004, Clinical Cancer Research.

[26]  R. Burger,et al.  Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  P. Franzone,et al.  Combined treatment with chemotherapy and radiotherapy in high-risk FIGO stage III-IV endometrial cancer patients. , 2004, Gynecologic oncology.

[28]  C. Eng,et al.  PTEN coordinates G1 arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model , 2001 .

[29]  P. Koper,et al.  Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. , 2000 .

[30]  P. Koper,et al.  Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial , 2000, The Lancet.

[31]  L. Schriml,et al.  Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. , 1999, Journal of the National Cancer Institute.

[32]  J. L. Bos,et al.  ras oncogenes in human cancer: a review. , 1989, Cancer research.

[33]  R. C. Macridis.  A review , 1963 .

[34]  Xiao Xu,et al.  The xCELLigence system for real-time and label-free monitoring of cell viability. , 2011, Methods in molecular biology.

[35]  R. Wenham,et al.  The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. , 2009, Cancer control : journal of the Moffitt Cancer Center.

[36]  M. Einstein,et al.  Pilot phase II trial of radiation "sandwiched" between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC). , 2008, Gynecologic oncology.

[37]  M. Carey,et al.  Adjuvant paclitaxel and carboplatin chemotherapy with involved field radiation in advanced endometrial cancer: a sequential approach. , 2007, International journal of radiation oncology, biology, physics.

[38]  C. Eng,et al.  PTEN coordinates G(1) arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model. , 2001, Human molecular genetics.